Overview

SWOG-9320 Combination Chemotherapy, Radiation Therapy, and Antiviral Therapy in Treating Patients With AIDS-Related Lymphoma

Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
0
Participant gender:
All
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells. Antiviral therapy may be effective treatment for AIDS-related lymphoma. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, radiation therapy, and antiviral therapy in treating patients who have AIDS-related lymphoma.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Southwest Oncology Group
Collaborator:
National Cancer Institute (NCI)
Treatments:
Bleomycin
Cyclophosphamide
Cytarabine
Doxorubicin
Etoposide
Etoposide phosphate
Lenograstim
Leucovorin
Levoleucovorin
Liposomal doxorubicin
Methotrexate
Prednisone
Sulfamethoxazole
Trimethoprim
Trimethoprim, Sulfamethoxazole Drug Combination
Vincristine
Criteria
DISEASE CHARACTERISTICS: Histologically proven intermediate or high grade non-Hodgkin's
lymphoma of one of the following histologies: Follicular, predominantly large cell Diffuse,
small cleaved cell Diffuse mixed, small and large cell Diffuse, large cell (cleaved or
noncleaved) Immunoblastic, large cell Small noncleaved cell, Burkitt's or non-Burkitt's No
lymphoblastic lymphoma Prior diagnosis of AIDS or HIV positivity required Confirmation of
HIV antibody status by Western blot mandatory Bidimensionally measurable or evaluable
disease No primary CNS lymphoma Concurrent registration on protocol SWOG-8947 (central
serum repository) required

PATIENT CHARACTERISTICS: Age: Over 18 Performance status: SWOG 0-2 Hematopoietic: Absolute
neutrophil count at least 500/mm3 Platelet count at least 75,000/mm3 Hepatic: AST no
greater than 1.5 times normal Alkaline phosphatase no greater than 1.5 times normal LDH no
greater than 1.5 times normal PT/PTT normal Renal: Creatinine no greater than 2.0 times
normal Creatinine clearance at least 60 mL/min Cardiovascular: No serious abnormalities on
EKG No history of severe coronary artery disease No history of cardiomyopathy, congestive
heart failure, or arrhythmia Other: No active uncontrolled infection No active second
malignancy within 5 years except adequately treated nonmelanoma skin cancer or adequately
treated carcinoma in situ of the cervix Not pregnant or nursing Fertile patients must use
effective contraception

PRIOR CONCURRENT THERAPY: No prior chemotherapy or radiotherapy for lymphoma